Showing 7941-7950 of 10548 results for "".
- Analysis: Pediatric Allergic Rhinitis Doubled in Japan Over 40 Yearshttps://practicaldermatology.com/news/analysis-pediatric-allergic-rhinitis-doubled-in-japan-over-40-years/2487238/A 40-year epidemiologic analysis published in the World Allergy Organization Journal showed an increases in allergic rhinitis (AR), allergic conjunctivitis (AC), and Japanese cedar pollinosis (JCP) among school-aged children in western Japan, while rates of atopic dermatitis (AD) and bro
- PanOxyl Portfolio Highlights Accessibility and Long-Term Acne Management During Virtual Desksidehttps://practicaldermatology.com/news/panoxyl-portfolio-highlights-accessibility-and-long-term-acne-management-during-virtual-deskside/2487257/Acne management requires a broader approach than simply targeting active breakouts, according to speakers during a virtual media deskside hosted by Revance. The discussion focused on over-the-counter acne management strategies with the PanOxyl brand as well as procedural options for acne scar tre
- Randomized Trial Evaluates Educational Delivery Methods for Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/randomized-trial-evaluates-educational-delivery-methods-for-pediatric-atopic-dermatitis/2487170/A randomized controlled trial published online in Pediatric Dermatology found that video-based therapeutic patient education (TPE) did not significantly outperform standard educational handouts for pediatric atopic dermatiti
- Isotretinoin Use in Adolescence Not Linked to Reduced Adult Height: Analysishttps://practicaldermatology.com/news/isotretinoin-use-in-adolescence-not-linked-to-reduced-adult-height-analysis/2487168/Concerns that isotretinoin therapy during adolescence could impair skeletal growth were not supported by findings from a large nationwide Danish study published in
- BE BOLD: Bimekizumab Tops Risankizumab for ACR50 Outcomeshttps://practicaldermatology.com/news/be-bold-bimekizumab-tops-risankizumab-for-acr50-outcomes/2487139/New phase 3 data from the BE BOLD trial indicated that bimekizumab (BIMZELX) achieved superior joint efficacy compared with risankizumab (SKYRIZI) in adults with active psoriatic arthritis (PsA), according to a press release from the manufacturer.
- Combination Ixekizumab and Tirzepatide Therapy Outperforms Ixekizumab Alone in Psoriasishttps://practicaldermatology.com/news/combination-ixekizumab-and-tirzepatide-therapy-outperforms-ixekizumab-alone-in-psoriasis/2487115/Concomitant treatment with ixekizumab (Taltz, Eli Lilly and Company) and tirzepatide (Zepbound, Eli Lilly and Company) led to superior skin clearance and quality-of-life outcomes compared with ixekizumab alone in adults with moderate-to-severe plaque psoriasis and
- Text-Messaging Program Improves Cardiovascular Risk Behaviors in Psoriasishttps://practicaldermatology.com/news/text-messaging-program-improves-cardiovascular-risk-behaviors-in-psoriasis/2487068/Structured text-messaging interventions were associated with an improvement cardiovascular risk-related behaviors and patient activation in adults with psoriasis, according to new study results published online in JAMA Dermatology.
- Meta-Analysis: HS Linked with Elevated Cardiovascular Riskhttps://practicaldermatology.com/news/meta-analysis-hs-linked-with-elevated-cardiovascular-risk/2487046/Patients with hidradenitis suppurativa (HS) may face an increased burden of cardiovascular disease, according to a new systematic review and meta-analysis in the British Journal of Dermatology. Study authors include
- Dr. Kevin Pinski Presents Injectable Pearls at Noahhttps://practicaldermatology.com/news/dr-kevin-pinski-presents-injectable-pearls-at-noah/2486902/At the 67th Noah Worcester Dermatological Society Annual Meeting, Kevin Pinski, MD, presented “Injectable Pearls,” drawing on nearly 4 decades of experience with neuromodulators, fillers, and cosmetic injectables. The presentation covered practical techniques, pati
- Analysis: PRS Improves Melanoma Risk Predictionhttps://practicaldermatology.com/news/tildrakizumab-matches-risankizumab-guselkumab-in-mid-term-psoriasis-outcomes/2486903/A polygenic risk score (PRS) improved prediction of invasive cutaneous melanoma when added to an established clinical risk model, according to findings from a recent genome-wide association analysis. The PRS was derived from a